Stockreport

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026

Sangamo Therapeutics, Inc.  (SGMO) 
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.sangamo.com
PDF Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical bene [Read more]